ADOCIA to Present New Data on AdoShell at Upcoming Scientific Conferences – Showcasing Potential Curative Treatment for Type 1 Diabetes - Seite 2

• AdoShell: A Permselective and Non-Fibrotic Scaffold for Human Islet Transplantation
  • Poster session
  • Clément Cocita, Ouardane Jouannot, Julie Brun, Camille Gautier, Nicolas Laurent, Karim Bouzakri, Jonna Saarimäki-Vire, Timo Otonkoski, Diego Balboa, Anne-Lise Gaffuri, Rosy Eloy, Olivier Soula

International Pancreas and Islet Transplant Association (IPITA) 2025 World Congress, Pisa, Italy, June 15-18, 2025

• AdoShell, a non-fibrotic encapsulation system for human islet transplantation without immunosuppression
  • Session: OP_03 Bioengineering the Future of Diabetes Therapy: 3D Printing, Organoids, and Immune-Protective Implants
  • Presentation: Monday, June 16, 2025 - 12:00 PM (CEST)
  • Ouardane Jouannot, Alexandre Martin, Julie Brun, Madeleine Frêlon, Camille Gautier, Guillaume Lefebvre, Romain Besnard, Clément Cocita, Claire Megret, Nicolas Laurent, Anne-Lise Gaffuri, Martin Gaudier, Rosy Eloy, François Pattou, Olivier Soula.

American Diabetes Association’s (ADA) 85^th Scientific Sessions, Chicago, USA, June 20-23, 2025

• AdoShell, a non-fibrotic encapsulation system, enables stem cell-derived islets in vivo maturation for T1DM treatment
  • Session: Innovation and Progress in Stem Cell–Derived Islet-Cell Replacement Therapy
  • Presentation: 139‑OR, Friday, June 20, 2025, 6:00 PM (CDT)
  • Ouardane Jouannot, Julie Brun, Clément Cocita, Alexandre Martin, Camille Gautier, Jonna Saarimäki-Vire, Timo Otonkoski, Diego Balboa, Nicolas Laurent, Anne-Lise Gaffuri, Rosy Eloy, Karim Bouzakri, Olivier Soula

Note: all information contained in the submitted abstracts should be considered preliminary and subject to change until the study data and observations are fully presented at the specified conferences. The abstracts are subject to embargo.

About Adocia

Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity.

The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone technology for the development of new generation insulins and products combining different hormones; 2) AdOral, an oral peptide delivery technology; 3) AdoShell, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel, a long-acting drug delivery platform.